MGC Pharmaceuticals (ASX:MXC) is a publicly-traded Australian company focused on the growing global Cannabinoids market. Founded by experienced veterans of the global Medical Cannabis Industry (which was crucial to the initial discovery and research of the Endocannabinoid system, and the Cannabinoids), MGC Pharmaceuticals brings many years of experience to its core focus and strategy of developing and supplying high quality Cannabinoids and the non-psychoactive Cannabidiol (CBD) to the emerging global market.
With licenses to grow Hemp in Europe, and with research projects taking place in Israel, Europe and Australia, MGC is using its seamless, highly supervised supply chain; from genetics and breeding through planting and all the way to extraction, to provide reliable products of the highest quality to the pharmaceutical and cosmetic industries. Our holistic approach ensures that MGC Pharmaceuticals will remain at the forefront of research, development and delivery in this rapidly growing and important sector of the industry, and specifically in the cosmetics industry via MGC Derma. In order to ensure top quality products MGC Derma, the cosmetics division of MGC Pharmaceuticals, has engaged with Dr. Burstein Cosmetics, a well-known and reputable manufacturer of cosmetics for numerous high-end lines. Dr. Burstein Cosmetics has a stellar reputation and many years of experience, as well as cutting edge research in the chemistry and natural cosmetics fields. In partnership with MGC Derma the companies have launched four lines of CBD Cosmetics products: Anti-Ageing, Essentials and Derma Plus; all are produced under EU GMP and ISO supervision, and all featuring MGC’s high-quality CBD extract. MGC Derma products work with the body’s natural system to support the skin’s response, which encourages repair & rejuvenation of the skin itself. MGC Derma is committed to using the most effective natural ingredients and have developed a methodology to employ the highest purity CBD available in our various product lines.